Deutsche Bank Ag\ Verve Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 41,695 shares of VERV stock, worth $225,569. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,695

Previous 26,832 55.39%

Holding current value

$225,569

Previous $130,000 54.62%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$4.4 - $7.86 $65,397 - $116,823	14,863 Added 55.39%	41,695 $201,000
Q2 2024 Aug 14, 2024	SELL	$4.76 - $12.79 $22,253 - $59,793	-4,675 Reduced 14.84%	26,832 $130,000
Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $54,785 - $91,021	5,068 Added 19.17%	31,507 $418,000
Q4 2023 Feb 14, 2024	SELL	$8.84 - $18.7 $11,191 - $23,674	-1,266 Reduced 4.57%	26,439 $368,000
Q3 2023 Nov 09, 2023	BUY	$11.42 - $20.82 $26,254 - $47,865	2,299 Added 9.05%	27,705 $367,000
Q2 2023 Aug 14, 2023	SELL	$13.34 - $19.9 $168,764 - $251,754	-12,651 Reduced 33.24%	25,406 $476,000
Q1 2023 May 15, 2023	BUY	$14.3 - $24.01 $175,032 - $293,882	12,240 Added 47.41%	38,057 $548,000
Q4 2022 Feb 13, 2023	BUY	$17.85 - $40.7 $96,157 - $219,250	5,387 Added 26.37%	25,817 $499,000
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $45,514 - $120,818	2,912 Added 16.62%	20,430 $702,000
Q2 2022 Aug 11, 2022	SELL	$11.14 - $23.17 $35,859 - $74,584	-3,219 Reduced 15.52%	17,518 $268,000
Q1 2022 May 13, 2022	BUY	$20.92 - $39.36 $225,224 - $423,749	10,766 Added 107.97%	20,737 $474,000
Q4 2021 Feb 11, 2022	BUY	$31.94 - $54.82 $16,289 - $27,958	510 Added 5.39%	9,971 $368,000
Q3 2021 Nov 04, 2021	BUY	$46.0 - $73.99 $435,206 - $700,019	9,461 New	9,461 $444,000

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $324M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account